Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06640049
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-10
Brief Title:
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Single-Arm Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage IIIII dMMRMSI-H Locally Advanced Rectal Cancer in China
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
China AZUR-1
Brief Summary:
The main goal of this study is to evaluate the effect of dostarlimab monotherapy in Chinese participants with locally advanced Mismatch-repair deficient dMMR Microsatellite instability-high MSI-H rectal cancer who have received no prior treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None